


Thank you  
to our sponsors!

*Programm changes reserved*



**Pharmore 1000 €**  
**Octapharma 500 €**  
**SOBI 500 €**  
**CSL Behring 300 €**  
**Novartis 300 €**

Requests / Information:  
carl-friedrich.classen@med.uni-rostock.de  
Tel. 0381 / 494 7255  
Fax. 0381 / 494 686 7255

The symposium will take place at the  
**Kinder- und Jugendklinik,**  
**Ernst-Heydemann-Str. 8, 18057 Rostock**



**ZOOM login-data:**

Friday:

<https://uni-rostock-de.zoom-x.de/j/64798248277?pwd=UDlvVjFvRXR6dV FVQWNTYIB5eVhldz09>

Saturday:

<https://uni-rostock-de.zoom-x.de/j/68660966274?pwd=TU1uZUJPUnpCc0 dvZWRJcUpyb3pEdz09>

Login data and Abstract booklet will also be sent upon request.

**Kinder- und Jugendklinik der  
Universitätsmedizin Rostock**  
Komm. Direktor Prof. Dr. M. Ballmann  
Ernst-Heydemann-Str. 8  
D - 18057 Rostock  
**AG Hirntumorforschung**  
Prof. Dr. med. Carl Friedrich Classen

**Kinder- und Jugendklinik**  
**Universitätsmedizin Rostock**



**Programme**

**18<sup>th</sup> ROSTOCK SYMPOSION**  
**for Tumor Immunology and Brain**  
**Tumor Research in Pediatrics**  
**Friday 16 and Sat. 17 Feb. 2024**  
**Hörsaal and Spielsaal**  
**Kinder- und Jugendklinik der**  
**Universitätsmedizin Rostock**

## **Preliminary Programme**

### **Friday 16 2 2024**

9:00 Welcome

#### **Immunology**

CSF results on exosomal microRNAs, cytokines, neurofilament light chain (NfL), and cellular analysis of patients with OV-treated brain malignancies  
*Christian Scheiber, Ulm*

New data on rare causes of thrombocytopenia, which need to be recognized by the pediatrician.

*Andreas Greinacher, Greifswald*

Leniolisib in APDS - Experiences from the Phase III and OLE Studies

*Julia Körholz, Dresden*

Functional single nucleotide polymorphisms (SNPs) linked to hyperinflammation, autoimmunity, malignancies and stem cell transplantation

*Marion Schneider, Ulm*

### **11: 00 Coffee Break**

Profound T-cell immune deficiency due to a novel biallelic LCK variant

*Anna Lisa Lanz, München*

Human Leukocyte Antigens (HLA) and Multiple Sclerosis

*Thomas Binder, Rostock*

#### **Oncology**

The serine/threonine-specific phosphatase PP2A as a possible target for glioblastoma therapy

*Michael Walter, Rostock*

### **13:00 Lunch**

14:00

Integration of Health-Related Quality of Life Assessment in Individualized Multimodal Immunotherapy

*Peter Van de Vliet, Köln*

Peptide-stimulation of autologous T cells reverts immune checkpoint inhibitor resistance of hypermutated colorectal cancer cells

*Sandra Schwarz, Rostock*

The role of the checkpoint inhibitors anti-PD-1 and anti-TIM-3 on the antigen-specific immune response against head and neck squamous cell carcinoma

*Carlotta Kaißer, Erlangen*

The current state of targeted therapy of LCH

*Dmitri Evseev, Moscow*

### **16:00 Coffee Break**

Liquid biopsy of ctDNA in routine diagnostics: A single center experience report

*Simon von Ameln, Köln*

Tackling noradrenergic-mesenchymal plasticity using epigenetic modulation combined with anti-GD2-based chemoimmunotherapy in high-risk neuroblastoma

*Sascha Troschke-Meurer, Greifswald*

#### **Brain tumors in vitro**

How is a recurrent Glioblastoma selected?

*Mike Andrew Westhoff, Ulm*

Anti-GD2-directed immunotherapy against glioblastoma multiforme can be enhanced using checkpoint blockade in vitro and in vivo and the role of Neutrophils and Natural killer cells

*Myriam Ghossein, Greifswald*

Dual blockade of EZH2 and CDK4/6 boosts antitumoral effects against Glioblastoma

*Thomas Freitag, Rostock*

### **20:00 Dinner – Networking and Discussion**

**BORWIN Restaurant**

## **Saturday 17.2.2024**

8:00 Wakeup

#### **Brain tumor clinical**

Neuroradiology in pediatric brain tumor, the perspective of the neuroradiological reference center

*Brigitte Bison, Augsburg*

Treatment strategies in Craniopharyngeomas

*Thomas Freiman, Rostock*

The HIT-REZ experience with MEMMAT-like therapy (modified and original)

*Lydia Rink, Essen*

#### **Brain tumors - experimental therapies**

Translational analysis of Tumor Treating Fields exposure on blood coagulation in Glioblastoma

*Daniel Dubinski, Rostock*

A peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas

*Niklas Graßl, Mannheim*

### **10:30 Coffee Break**

Multiphase combined treatment for GBM: update and expansion of patient data

*Stefaan van Gool, Köln*

From bulk to spatial in melanoma brain metastases

*Josefine Radke, Greifswald*

Immunomodulatory effects of moderate, fever-range whole body hyperthermia; project presentation

*Timo Huber, Köln*

Medical Gas Plasma Technology Combines with Antimelanoma Therapies and Promotes Immune-Checkpoint Therapy Responses

*Sander Bekeschus*

13:00 Farewell